Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
Woessner FJR.
Matrix metalloproteinases and their inhibitors in connective tissue remodeling.
FASEB J, 5 (1991), pp. 2145-2154
[2.]
Woessner FJR.
Literature on vertebrate matrix metalloproteinases and their tissue inhibitors.
Matrix, 1 (1991), pp. 425-501
[3.]
L.M. Matrisian.
The matrix-degrading metalloproteinases.
Bio-Essays, 14 (1992), pp. 455-463
[4.]
H. Nagase, A.J. Barrett, J.R. Woessner.
Nomenclature and glossary of the matirx metalloproteinases.
Matrix, 1 (1992), pp. 421-424
[5.]
Woessner FJR.
The family of matrix metalloproteinases.
Ann N Y Acad Sci, 732 (1994), pp. 11-21
[6.]
N. Borkakoti.
Matrix metalloproteinases: variations on a theme.
Prog Biophys Mol Biol, 70 (1998), pp. 73-94
[7.]
H. Birkedal-Hansen, W.G.I. Moore, M.K. Bodden, L.J. Windsor, B. Birkedal-Hansen, A. De Carlo, et al.
Matrix metalloproteinases: a review.
Crit Rev Oral Bio Med, 4 (1993), pp. 197-250
[8.]
H. Kinoh, H. Sato, Y. Tsunezuka, T. Takino, A. Kawashima, Y. Okada, et al.
MT-MMP, the cell surface activator of proMMP-2 (pro-gelatinase A), is expressed with its substrate in mouse tissue during embryogenesis.
J Cell Sci, 109 (1996), pp. 953-959
[9.]
V. Knauper, H. Will, C. López-Otin, B. Smith, S.J. Atkinson, H. Stanton, et al.
Cellular mechanisms for human procollagenase-3 (MMP-13) activation: evidence that MT1-MMP and gelatinase A are able to generate active enzyme.
J Biol Chem, 271 (1996), pp. 17124-17131
[10.]
E.N. Baramova, K. Bajou, A. Remacle, C. L'Hoir, H.W. Krell, U.H. Weidle, et al.
Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation.
FEBS Lett, 405 (1997), pp. 157-162
[11.]
M.C. Vissers, C.C. Winterbourn.
Activation of human neutrophil gelatinase by endogenous serine proteases.
Biochem J, 249 (1988), pp. 327-331
[12.]
S. Rajagopalan, X.P. Meng, S. Ramasamy, D.G. Harrison, Z.S. Galis.
Reactive oxygen species produced by macrophage-derivedfoams cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability.
J Clin Invest, 98 (1996), pp. 2572-2579
[13.]
C. Heussen, E.B. Dowle.
Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecylsulfate and copolymerized substrate.
Anal Biochem, 102 (1980), pp. 196-202
[14.]
G. Sawicki, E. Salas, J. Murat, H. Mistza-Lane, M.W. Radomski.
Release of gelatinase B during platelet activation mediates aggregation.
Nature, 386 (1997), pp. 616-619
[15.]
C.F. Jin, M. Mata, D.J. Fink.
Rapid construction of deleted DNA fragments for use as internal standards in competitive PCR.
PCR Methods Appl, 3 (1994), pp. 252-255
[16.]
J.L. Cordell, B. Falini, W.N. Erber, A.K. Ghosh, Z. Abdulaziz, S. Mac-Donald, et al.
Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal antialkaline phosphatase (APAAP complexes).
J Histochem Cytochem, 32 (1984), pp. 219-229
[17.]
J.M. Ray, W.G. Stetler-Stevenson.
The role of metalloproteinases and their inhibitors in tumor, metastasis, and angiogenesis.
Eur Respir J, 7 (1994), pp. 2062-2072
[18.]
L.A. Liotta, K. Tryggvason, S. Garbisa, I. Hart, C.M. Foltz, S. Shafie.
Metastasic potential correlates with enzymatic degradation of basament membrane collagen.
Nature, 284 (1980), pp. 67-68
[19.]
C.F. Sier, F.J. Kubben, S. Ganesh, M.M. Heerding, G. Griffioen, R. Hanemaaijer, et al.
Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma.
Br J Cancer, 74 (1996), pp. 413-417
[20.]
G.I. Murray, M.E. Duncan, E. Arbuckle, W.T. Melvin, J.E. Fothergill.
Matrix metalloproteinases and their inhibitors in gastric cancer.
Gut, 43 (1998), pp. 791-797
[21.]
K. Tryggvason, M. Hoyhta, M. Pyke.
Type IV collagenases in invasive tumors.
Breat Cancer Res Treat, 24 (1993), pp. 209-218
[22.]
G. Schwartz, H. Wang, N. Lampen, N. Altorki, D. Kelsen, A.P. Albino.
Defining the invasive phenotype of proximal gastric cells.
Cancer, 56 (1994), pp. 500-505
[23.]
T. Inoue, M. Yashiro, S. Nishimura, K. Maeda, T. Sawada, Y. Ogawa, et al.
Matrix metalloproteinase-1 expression is a prognostic factor for patients with advancced gastric cancer.
Int J Mol Med, 4 (1999), pp. 73-77
[24.]
H. Ajisaka, S. Fushida, Y. Yonemura, K. Miwa.
Expression of insulin-like growth factor-2, c-MET, matrix metalloproteinase-7 and MUC-1 in primary lesions and lymph node metastatic lesions of gastric cancer.
Hepatogastroenterology, 48 (2001), pp. 1788-1792
[25.]
J.M. Del Casar Lizcano, F. Vizoso Pineiro, L.O. González-Sánchez, A. Martín Suárez, R. Gava, E. Cuesta Fernández, et al.
Expresión y significado clínico de la colagenasa-3 (MMP-13) en el cáncer gástrico.
Gastroenterol Hepatol, 26 (2003), pp. 1-7
[26.]
A. Elnemr, Y. Yonemura, E. Bandou, K. Kinoshita, T. Kawamura, S. Takahashi, et al.
Expression of collagenase-3 (matrix metalloproteinase-13) in human gastric cancer.
Gastric Cancer, 6 (2003), pp. 30-38
[27.]
E. Roeb, C.G. Dietrich, R. Winograd, M. Arnd, B. Breuer, J. Fass, et al.
Activity and cellular origin of gelatinases in patients with colon and rectal carcinoma differential activity of matrix metalloproteinase-9.
Cancer, 92 (2001), pp. 2680-2691
[28.]
E.T. Waas, R.M. Lomme, J. DeGroot, T. Wobbes, T. Hendriks.
Tissue levels of active matrix metalloproteinase-2 and -9 in colorectal cancer.
Br J Cancer, 86 (2002), pp. 1876-1883
[29.]
P. Behrens, M. Mathiak, E. Mangold, S. Kirdorf, A. Wellmann, F. Fogt, et al.
Stromal expression of invasion-promoting, matrix-degrading proteases MMP-1 and -9 and the Ets 1 transcription factor in HNPCC carcinomas and sporadic colorectal cancers.
Int J Cancer, 107 (2003), pp. 183-188
[30.]
M.G. Tutton, M.L. George, S.A. Eccles, S. Burton, S.I. Swift, A.M. Abulafi.
Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients.
Int J Cancer, 107 (2003), pp. 541-550
[31.]
A.V. Ougolkov, K. Yamashita, M. Mai, T. Minamoto.
Oncogenic beta-catenin and MMP-7 (matrilysin) cosegregate in late-stage clinical colon cancer.
Gastroenterology, 122 (2002), pp. 60-71
[32.]
S. Horiuchi, H. Yamamoto, Y. Min, Y. Adachi, F. Itoh, K. Imai.
Association of ets-related transcriptional factor E1AF expression with tumour progression and overexpression of MMP-1 and matrilysin in human colorectal cancer.
J Pathol, 200 (2003), pp. 568-576
[33.]
C. Rivat, N. Le Floch, N. Sabbah.
Synergistic cooperation between the AP-1 and LEF-1 transcription factors in activation of the matrilysin promoter by the src oncogene: implications in cellular invasion.
FASEB J, 17 (2003), pp. 1721-1723
[34.]
T. Tomita, K. Iwata.
Matrix metalloproteinases and tissue inhibitors of metalloproteinases in colonic adenomas-adenocarcinomas.
Dis Colon Rectum, 39 (1996), pp. 1255-1264
[35.]
R.K. Yantiss, M.W. Bosenberg, D.A. Antonioli, R.D. Ozde.
Utility of MMP-1, p53, E-cadherin, and collagen IV immunohistochemical stains in the differential diagnosis of adenomas with misplaced epithelium versus adenomas with invasive adenocarcinoma.
Am J Surg Pathol, 26 (2002), pp. 206-215
[36.]
K. Yamashita, M. Mori, T. Shiraishi, K. Shibuta, K. Sugimachi.
Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma.
Clin Cancer Res, 6 (2000), pp. 1169-1174
[37.]
K. Ohashi, T. Nemoto, K. Nakamura, R. Nemori.
Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas.
Cancer, 88 (2000), pp. 2201-2209
[38.]
M.T. Salmela, M.L. Karjalainen-Lindsberg, P. Puolakkainen, U. Saarialho-Kere.
Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma.
Br J Cancer, 85 (2001), pp. 383-392
[39.]
M. Maatta, Y. Sioni, A. Liakka, H. Autio-Harmainen.
Differential expression of matrix metalloproteinase (MMP)-2, MMP-9, and membrane type 1-MMP in hepatocellular and pancreatic adenocarcinoma: implications for tumor progression and clinical prognosis.
Clin Cancer Res, 6 (2000), pp. 2726-2734
[40.]
H.C. Crawford, C.R. Scoggins, M.K. Washington, L.M. Matrisian, S.D. Leach.
Matrix metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates acinar-to-ductal metaplasia in exocrine pancreas.
J Clin Invest, 109 (2002), pp. 1437-1444
[41.]
G. Ghilardi, M.L. Biondi, J. Mangoni, S. Leviti, M. DeMonti, E. Guagnellini, et al.
Matrix metalloproteinase-1 promoter polymorphism 1G/2G is correlated with colorectal cancer invasiveness.
Clin Cancer Res, 7 (2001), pp. 2344-2346
[42.]
X. Miao, C. Yu, W. Tan, P. Xiong, G. Liang, W. Lu, et al.
A functional polymorphism in the matrix metalloproteinase-2 gene promoter (–1306C/T) is associated with risk of development but not metastasis of gastric cardia adenocarcinoma.
Cancer Res, 63 (2003), pp. 3987-3990
[43.]
T. Matsuoka, M. Yashiro, T. Sawada, T. Ishikawa, M. Ohira, K. Hirakawa.
Effect of a matrix metalloproteinase inhibitor on a lymph node metastatic model of gastric cancer cells passaged by orthotopic implantation.
J Exp Clin Cancer Res, 20 (2001), pp. 213-218
[44.]
H. Maki, K. Hojo, H. Tanaka, T.Y. Sawada, R. Maekawa, T. Yoshioka.
Augmented anti-metastatic efficacy of a selective matrix metalloproteinase inhibitor, MMI-166, in combination with CPT-11.
Clin Exp Metastasis, 19 (2002), pp. 519-526
[45.]
T. Aparicio, S. Kermorgant, V. Dessirier, M.J. Lewin, T. Lehy.
Matrix metalloproteinase inhibition prevents colon cancer peritoneal carcinomatosis development and prolongs survival in rats.
Carcinogenesis, 20 (1999), pp. 1445-1451
[46.]
K. Oba, H. Konno, T. Tanaka, M. Baba, K. Kamiya, M. Ohta, et al.
Prevention of liver metastasis of human colon cancer by selective matrix metalloproteinase inhibitor MMI-166.
Cancer Lett, 175 (2002), pp. 45-51
[47.]
A. Rosemurgy, J. Harris, A. Langleben, E. Casper, S. Goode, H. Rasmussen.
Marimastat in patients with advanced pancreatic cancer: a dose-finding study.
Am J Clin Oncol, 22 (1999), pp. 247-252
[48.]
S.R. Bramhall, J. Schulz, J. Nemunaitis, P.D. Brown, M. Baillet, J.A. Buckels.
A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer.
Br J Cancer, 87 (2002), pp. 161-167
[49.]
M.C. Meikle, S.J. Atkinson, R.V. Ward, G. Murphy, J.J. Reynolds.
Gingival fibroblasts degrade type I collagen films when stimulated with tumor necrosis factor and interlukin 1: evidence that breakdown is mediated by metalloproteinases.
J Periodontal Res, 24 (1989), pp. 207-213
[50.]
R.C. Page.
The pathobiology of periodontal diseases may affect systemic disease: inversion of paradigm.
N Periodontol, 3 (1998), pp. 108-120
[51.]
C.J. Bailey, R.M. Hembry, A. Alexander, M.H. Irving, M.E. Grant, C.A. Shuttleworth.
Distribution of the matrix metalloproteinases stromelysin, gelatinases A and B and collagenase in Crohn's disease and normal intestine.
J Clin Pathol, 47 (1994), pp. 113-116
[52.]
S. Pender, S. Tickle, A. Docherty, D. Howie, N.C. Wathen, T.T. Mac-Donald.
A major role for matrix metalloproteinases in T cell injury in the gut.
J Immunol, 158 (1997), pp. 1582-1590
[53.]
S. Pender, J. Fell, S.M. Chamow, A. Ashkenazi, T.T. MacDonald.
A p55 TNF receptor immunoadhesin prevents T cell-mediated intestinal injury by inhibiting matrix metalloproteinases production.
J Immunol, 160 (1998), pp. 4098-4103
[54.]
M. Baugh, M. Perry, A. Hollander, D.R. Davies, S.S. Cross, A.J. Lobo, et al.
Matrix metalloproteinases levels are elevated in inflammatory bowel disease.
Gastroenterology, 117 (1999), pp. 814-822
[55.]
B. Von Lampe, B. Barthel, S.E. Coupland, E.O. Riecken, S. Rosewicz.
Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease.
Gut, 47 (2000), pp. 63-73
[56.]
R.B. Heuschkel, T.T. MacDonald, G. Monteleone, M. Bajaj-Elliott, J.A. Smith, S.L. Pender.
Imbalance of stromelysin 1 and TIMP 1 in the mucosal lesions of children with inflammatory bowel disease.
Gut, 47 (2000), pp. 57-62
[57.]
A. Stallmach, C.C. Chan, K-W Ecker, G. Feifel, H. Herbst, D. Schuppan, et al.
Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis.
Gut, 47 (2000), pp. 415-422
[58.]
J.F. Tarlton, C.V. Whiting, D. Tunmore, S. Bregenholt, J. Reimann, M.H. Claesson, et al.
The role of up-regulated serine proteases and matrix metalloproteinases in the pathogenesis of a mourine model of colitis.
Am J Pathol, 157 (2000), pp. 1927-1935
[59.]
C. Medina, S. Videla, A. Radomski, M.W. Radomski, M. Antolin, F. Guarner, et al.
Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis.
Am J Physiol Gastrointest Liver Physiol, 284 (2003), pp. G116-G122
[60.]
C. Medina, S. Videla, A. Radomski, M.W. Radomski, M. Antolin, F. Guarner, et al.
Therapeutic effect of phenantroline in two rat models of inflammatory bowel disease.
Scand J Gastroenterol, 36 (2001), pp. 1314-1319
[61.]
A.P. Sykes, R. Bhogal, C. Brampton, C. Chander, C. Whelan, M.E. Parsons, et al.
The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease.
Aliment Pharmacol Ther, 13 (1999), pp. 1535-1542
[62.]
S. Daum, U. Bauer, H.D. Foss, U. Wahnschaffe, D. Schuppan, H. Stein, et al.
Increased expression of mRNA for matrix metalloproteinases-1 and -3 and tissue inhibitor of metalloproteinases-1 in intestinal biopsy specimens from patients with coeliac disease.
Gut, 44 (1999), pp. 17-25
Copyright © 2004. Elsevier España, S.L.. Todos los derechos reservados
